Loading…
← CockpitCompetitor Analysis › AMPH Amphastar Pharmaceuticals, Inc.Open in the cockpit ↗

Amphastar Pharmaceuticals, Inc.AMPHCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Makes generic injectable, inhalation and insulin drugs, including naloxone and Primatene Mist asthma inhaler.

Momentum leader 96
Mkt cap
$1.27B
US dollars, full cap
Free float
73%
of shares outstanding
$/day
$13.6M
20-day average traded
Fwd P/E
9.1×
forward earnings
ROIC−WACC
+0.4 pp
WACC 8.3%
Hurdle
-13 pp
Req g minus delivered
Next earnings
106 days
4 Mar 2027
Close · USD$29.71
1D+2.1%
1W+3.9%
1M+14.5%
3M+37.0%
6M+64.3%
YTD+10.9%
1Y+14.2%
ATR %3.7%
Beta0.45
52w lowhigh4.2% off high

What Amphastar Pharmaceuticals does

Makes generic injectable, inhalation and insulin drugs, including naloxone and Primatene Mist asthma inhaler.

Builds profit on products with few competitors, making complex injectables and inhalers itself and selling mainly to wholesalers that supply hospitals and pharmacies. Baqsimi, a nasal glucagon for severe low blood sugar acquired from Eli Lilly in 2023, added a branded product to a mostly generic range.

Products and services

  • Naloxone (opioid overdose reversal)
  • Epinephrine injectables
  • Primatene Mist (OTC asthma)
  • Insulin (generic)

Customers

  • Hospitals
  • Emergency responders
  • Retail pharmacies

Where it sits in the supply chain

  • Generic pharmaceutical manufacturing
  • Injectable/inhalation drug production
  • Hospital/retail pharmacy distribution

What could go right

  • Naloxone demand from opioid-crisis response
  • New generic drug launches

What could go wrong

  • Generic pricing pressure/competition
  • Manufacturing/FDA quality compliance risk

Moat: narrow (scale, regulatory licence, cost advantage). Vertically integrated manufacturing of complex generics/injectables is costly for smaller rivals to replicate.

Headquarters: Rancho Cucamonga, California, US · Founded: 1996 · Employees: 1,976

Named competitors

Amphastar Pharmaceuticals at a glance

Size Amphastar Pharmaceuticals (AMPH) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $1.27B, the 2084th largest of 3,085 United States companies the cockpit tracks. Shares closed at $29.71 on 18 Nov 2026.

Performance Over six months the shares gained 64.3%, against -15.6% for the median peer and -2.2% for the United States market (cap-weighted) — highest of 20 in its peer set.

Growth Revenue grew 3.1% over the last twelve months (peer median +7.6%); the operating margin is 18.7% (peer median 0.8%).

Valuation It trades at 9.1× forward earnings against a peer median of 24.0× (cheapest of 11).

Price implies For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is +16%, so the hurdle is -13 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 0.4 points above its cost of capital (8.3% WACC).

Credit Amphastar Pharmaceuticals has 1 bond outstanding ($345M).

Short interest Short interest is 10.0% of the free float (30 Oct 2026).

Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).

Relative performance

10012515021 May 202621 Aug 202618 Nov 2026AMPH 164Peer median 85
Six months, rebased to 100: Amphastar Pharmaceuticals against the median of its 20 peers (local-currency closes).

Amphastar Pharmaceuticals financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$746M$720M$732M$644M$499M
Revenue growth—-2%+14%+29%—
Gross profit$334M$341M$361M$344M$239M
EBITDA$206M$204M$263M$241M$136M
Net income$99.0M$98.1M$160M$138M$91.4M
Free cash flow$139M$121M$172M$145M$64.7M
Capital expenditure$131M$37.1M$41.0M$38.2M$24.0M
Total debt$692M$656M$651M$624M$103M

Quarterly statements and history in the cockpit →

Amphastar Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%300204002332GHRS688076GPCRLBRXAVLNOCULINVAMNKDIDIA688293347850068760002099HROWAMPH6-month return →1-month return →
Up and to the right = strong over both horizons. Amphastar Pharmaceuticals is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×200×400×300204002332688076000950301263MNKD300026688293AMPHRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Amphastar Pharmaceuticals is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%-20%0%20%002332688076INVA300026688293068760AMPHGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Amphastar Pharmaceuticals is the large dot.

Amphastar Pharmaceuticals competitors and peer comparison

Head to head with its named competitors (AMPH vs HIK.L vs TEVA)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Amphastar Pharmaceuticals AMPH$1.27B+64%+3%19%9.1×2.5%
Hikma Pharmaceuticals HIK.L$4.58B+15%+2%20%9.8×2.0%
Teva Pharmaceutical Industries Limited Sponsored ADR TEVA$49.3B+23%-4%19%15.0×10.5%

How Amphastar Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Amphastar Pharmaceuticals against its 20 peers (data as of 18 Nov 2026)
MeasureAMPHPeer medianRank in peer set
1-month return+14.5%-5.1%3rd highest of 20
6-month return+64.3%-15.6%highest of 20
Distance from 52-week high-4.2%-38.9%highest of 20
Revenue growth (TTM)+3.1%+7.6%8th lowest of 16
Operating margin18.7%0.8%2nd highest of 16
Forward P/E9.1×24.0×cheapest of 11
Growth the price implies (Req g, 7 yrs)2.5%5.2%3rd least demanding of 7
Growth delivered (Del g)+15.5%+11.0%4th highest of 7
Hurdle (Req g minus delivered)-13.0 pp-3.4 pp3rd least demanding of 7
ROIC minus cost of capital+0.4 pp-5.6 pp5th highest of 16
EV / EBITDA8.4×19.0×2nd cheapest of 4
Net debt / EBITDA2.2×4.7×3rd least indebted of 5

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Amphastar Pharmaceuticals AMPHUnited States$1.27B+64%+3%19%9.1×2.5%+15.5%
Staidson (Beijing) Biopharmaceuticals 300204.SZChina$1.26B-41%-24%-51%522.3×n/an/a
Zhejiang Xianju Pharmaceutical 002332.SZChina$1.28B-1%+8%11%17.7×-0.4%-1.3%
GH Research GHRSUnited States$1.25B-19%n/an/an/an/an/a
Sinopep-Allsino Bio Pharmaceutical 688076.SSChina$1.25B-16%+14%19%11.9×3.4%+27.9%
C.Q. Pharmaceutical 000950.SZChina$1.24B-27%-3%1%18.6×n/an/a
Guangdong Taienkang Pharmaceutical 301263.SZChina$1.30B-24%+2%-2%60.7×n/an/a
Structure Therapeutics, Inc. Sponsored ADR GPCRUnited States$1.24B-53%n/an/an/an/an/a
LB Pharmaceuticals LBRXUnited States$1.30B+43%n/an/an/an/an/a
Avalyn Pharma AVLNUnited States$1.23B-1%n/an/an/an/an/a
Ocular Therapeutix OCULUnited States$1.31B-26%-10%-681%n/an/an/a
Innoviva INVAUnited States$1.31B-17%+12%38%9.5×-17.2%+3.9%
MannKind MNKDUnited States$1.31B+25%+32%-2%174.4×n/an/a
Tianjin Chase Sun Pharmaceutical 300026.SZChina$1.23B-10%-29%3%21.3×7.0%-5.3%
Idorsia IDIA.SWSwitzerland$1.22B-9%-5%-70%n/an/an/a
Windward Bio WWBUnited States$1.31Bn/an/an/an/an/an/a
Shanghai OPM Biosciences 688293.SSChina$1.32B+36%+133%11%48.6×25.9%+23.1%
D&D Pharmatech 347850.KSSouth Korea$1.22B-49%-77%-2,324%n/an/an/a
Celltrion Pharm 068760.KSSouth Korea$1.33B-23%+16%12%n/a10.2%+18.1%
Zhejiang Hisoar Pharmaceutical 002099.SZChina$1.33B-2%+9%-13%n/an/an/a
Harrow HROWUnited States$1.21B+4%+21%1%26.8×n/an/a

Amphastar Pharmaceuticals bonds and credit

Amphastar Pharmaceuticals has 1 bond outstanding with $345M face value.

Every bond, yield and spread in the cockpit →

Questions

Who are Amphastar Pharmaceuticals's main competitors?
Named competitors: Hikma Pharmaceuticals (HIK.L), Fresenius Kabi (private or unlisted), Teva Pharmaceutical (TEVA). The cockpit's measured peer set (industry) also includes Staidson (Beijing) Biopharmaceuticals (300204.SZ), Zhejiang Xianju Pharmaceutical (002332.SZ), GH Research (GHRS), Sinopep-Allsino Bio Pharmaceutical (688076.SS), C.Q. Pharmaceutical (000950.SZ), Guangdong Taienkang Pharmaceutical (301263.SZ).
Is Amphastar Pharmaceuticals expensive compared with its peers?
On forward p/e it trades at 9.1× against a peer median of 24.0×, cheapest of 11 in its peer set. For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is +16%, so the hurdle is -13 pp: the price already allows for a slowdown.
How has Amphastar Pharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned +64.3% against -15.6% for the median peer; over one year +14.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.